AgeX Therapeutics is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West PhD initially as a subsidiary of BioTime Inc. with backing from British billionaire investor Jim Mellon and others.
West formerly served as CEO of BioTime and Advanced Cell Technology and founded Geron Corporation in 1990. The company’s vice president of new technology discovery is Aubrey de Grey PhD, who also serves as chief scientific officer of the SENS Research Foundation. The chairman is Gregory Bailey MD, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.
Competitors include Alphabet Inc.’s Calico, Unity Biotechnology, and Samumed.